Stock Ratings / Health Care / NTHI / financials

PLYX (31) RTSN (48) COYA (35) GNLX (29) ⌘ Pro Terminal →

NeOnc Technologies Holdings Inc. (NTHI) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$3.26 +4.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.28

NeOnc Technologies Holdings Inc. (NTHI) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $92.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NTHI Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NTHI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, NeOnc Technologies Holdings Inc. (NASDAQ: NTHI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $3.26 (+4.49% 1D, market cap $92.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NTHI ranks #749 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NTHI compare to PLYX and RTSN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NTHI carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PLYX (Polaryx Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $92.7M) and RTSN (Retension Pharmaceuticals Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $93.2M). Among the 5-stock peer group, NTHI leads on earnings multiple (N/A) while NTHI leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NTHI?

▼

Per NTHI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001979414), NeOnc Technologies Holdings Inc. generated $40.0K in revenue (-51.8% YoY), -$62.1M in net income, and -$20.4M in free cash flow against $2.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.28 (+0.62%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-11.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NTHI)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY NTHI SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.73-0.4% Next Q

Q2 (-2Q)

Grade E$2.72+3.7% Next Q

Q3 (-1Q)

Grade E$2.82+15.6% Next Q

Current

Grade E$3.26-8.9% Hist 90D α

Trajectory: E (25) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NTHI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NTHI currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.45) and Max Pain ($3.42) forces dealer call-delta covering toward $12.60.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NTHI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NTHI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How NTHI Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY24

Rev $83.0K

FY25

Rev $40.0K

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$40.0K	52%	-80%	-$62.1M	-$20.4M	-45%
FY 2024	$83.0K	52%	-80%	-$11.9M	-$4.2M	-45%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NTHI)

✓Walkthrough of NTHI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NTHI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -21.26%▼ DESCENDING CHANNEL

2026-11-02O $3.22H $3.37L $3.10C $3.26VOL 36.6K

RES: $5.05SUP: $2.36SMA50: $3.45SMA200: $5.44

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NTHI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NTHI Butterfly Map → + Track NTHI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -51.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NTHI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NTHI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NTHI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NTHI)

Health Care Rank #749 of 1016 ⚔️ PLYX vs NTHI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NTHI vs. PLYX, RTSN, COYA, GNLX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, NeOnc Technologies Holdings Inc. (NTHI) ranks #749 by composite RQD confidence (33/100, grade E) and #672 by equity capitalization ($92.9M). Within this direct 5-issuer industry benchmark cohort, NTHI leads on earnings valuation at N/A trailing P/E, while NTHI leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RTSN currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with NTHI at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NTHI ACTIVE NeOnc Technologies Holdings Inc.	E	33/100	—	—	-35.0%	+4.49%	$92.9M	Benchmark Subject
PLYX Polaryx Therapeutics Inc.	E	31/100	—	—	-35.0%	-5.91%	$92.7M	/plyx-vs-nthi →
RTSN Retension Pharmaceuticals Inc.	D	48/100	—	—	—	-3.97%	$93.2M	/rtsn-vs-nthi →
COYA Coya Therapeutics Inc.	D-	35/100	—	—	-35.0%	-9.30%	$93.4M	/coya-vs-nthi →
GNLX Genelux Corporation	E	29/100	—	—	-35.0%	-0.95%	$95.0M	/gnlx-vs-nthi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001979414

In its most recent audited fiscal period (FY2025, filed 2025-12-31), NeOnc Technologies Holdings Inc. (NTHI) reported GAAP revenue of $40.0K (-51.8% vs. FY2024 revenue of $83.0K ) , GAAP net income of -$62.1M, operating cash flow of -$20.4M, and free cash flow of -$20.4M (-383.3% YoY). On the balance sheet, NTHI closed FY2025 with $2.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$40.0K	-$62.1M	-$20.4M	-$20.4M	$2.8M	—
FY2024 (FY)	2024-12-31	$83.0K	-$11.9M	-$4.2M	-$4.2M	$3.4M	—

3. NTHI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NTHI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NTHI compare to PLYX and RTSN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NTHI?

Where is NTHI trading relative to its 50-day, 200-day, and 52-week technical levels?

NTHI last traded at $3.26 (+4.49% on volume of 131,704 shares), positioning the stock -5.51% below its 50-day simple moving average ($3.45) and -40.07% below its 200-day simple moving average ($5.44). Across its 52-week range of $2.50 to $12.00, NTHI sits at the 8.0% percentile with a 14-day RSI of 50.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.85 to $3.67).

NTHI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is NeOnc Technologies Holdings Inc. (NTHI)?

In FY 2025 (10-K), NTHI converted $1.0M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: NTHI RQD Cockpit NTHI 12M Forecast NTHI Earnings & Move NTHI Dividends & DRIP NTHI Insiders & 13F NTHI Whale Options NTHI Profit Sankey NTHI News & Why

ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

NTHI — NeOnc Technologies Holdings Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:44:23Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, NTHI scores 33 out of 100 and receives a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars: the Fundamental Cash Engine scores 7/20 (ROIC of -35%; FCF yield of -21.93%), indicating the business is consuming rather than generating cash. Whale/13F Flow scores 10/20, reflecting institutional accumulation and options positioning that is moderate rather than decisive. Insider Conviction scores 3/20 on SEC Form 4 and Congressional PTR cluster flow, the weakest pillar and a signal of limited insider confidence. Macro Regime Fit scores 6/20 with a Beta of 1.0 and sector sensitivity. Forensic Balance Sheet scores 7/20 with an Altman Z-Score of 2.5, a Piotroski F-Score of 1/9, and a Debt/Equity ratio of 0.5. For a prospective investor evaluating the stock today, the rating points to negative operating economics, weak insider signaling, and forensic red flags, which together weigh heavily against the upside case. Any potential upside would depend on a sustained operating turnaround that the reported financials do not yet show.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-58.2M	$-62.1M	N/A	$-20.4M	$0.1M	N/A
FY 2024	$0.1M	$-7.1M	$-11.9M	N/A	$-4.2M	$0.1M	N/A

Per the SEC financials, operating losses widened from $-7.1M in FY 2024 to $-58.2M in FY 2025, and net income fell from $-11.9M to $-62.1M. Operating, net, and gross margins are reported as -60%, -60%, and 0% respectively per the market data section, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, with a Debt/Equity ratio of 0.5. Cash is reported at $0.1M in both periods, and debt is N/A in the financial data.

Recent Catalysts & News Wire Analysis

Per the recent news wire, catalysts center on clinical and scientific communications: a study in which 48.9% were alive without worsening disease at six months, a pediatric case report of a patient breathing without a ventilator, and a planned presentation of NEO100 and NEO212 program data at the 31st Annual Meeting of the Society for Neuro-Oncology. Other items reference market action, including a report of breaking above key resistance on strong volume ahead of a Fox Business appearance and Abu Dhabi milestones. All five items are rated YELLOW. Per the Butterfly Supply-Chain Graph, no proprietary signals are present (supply_chain: NONE; butterfly_links: none; proprietary_signals: none). Risk watch items include the widening operating losses in the SEC financials and the weak Insider Conviction pillar, which are not offset by any signal in the graph.

Open Questions

What are NTHI's revenue sources, and what drove the decline to $0.0M in FY 2025 from $0.1M in FY 2024?
What is the company's cash runway given $0.1M in reported cash against $-20.4M in FY 2025 free cash flow, and how is it being funded?
What is the debt position, since reported debt is N/A despite a Debt/Equity ratio of 0.5?
What institutional (13F) and insider (Form 4) holdings exist, given the holders section is NONE?
Are the clinical data readouts referenced in the news wire tied to specific regulatory milestones or partnerships?

NTHI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for NeOnc Technologies Holdings Inc. (NTHI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NTHI Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 3h ago

NeOnc Technologies Holdings, Inc. (NTHI) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 6h ago

NeOnc Technologies Holdings, Inc. Estimates – NASDAQ:NTHI

TradingView report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 9h ago

In a brain cancer study, 48.9% were alive without worsening disease at six months.

Stock Titan report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 12h ago

NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology

Yahoo Finance report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Quiver Quantitative • 15h ago

NeOnc Technologies Holdings Breaks Above Key Resistance on Strong Volume Ahead of Fox Business Appearance and Abu Dhabi Milestones

Quiver Quantitative report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 18h ago

A 3-year-old with an aggressive brain tumor is breathing without a ventilator, doctors report.

Stock Titan report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Quiver Quantitative • 21h ago

NeOnc Technologies Holdings Signs Abu Dhabi MoU to Advance Brain Cancer Research and Clinical Development

Quiver Quantitative report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Two Abu Dhabi children are receiving an investigational brain cancer treatment; a third is expected to join this week.

Stock Titan report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NTHI Bull vs. Bear Conversation Board — What's Your Call at $3.26?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NTHI 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.75 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is NTHI (E • RQD 33/100) a Buy at $3.12?

Welcome to the NTHI (NeOnc Technologies Holdings Inc.) Roar Pit. Current RQD Composite is 33/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.56 (-17.9%)

Spot @ $3.12

Pump the brakes on NTHI — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on NTHI, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless NeOnc Technologies Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.62 (+16.0%)

Spot @ $3.12

NTHI cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on NTHI, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.12 (52-wk range $2.80 - $3.48), any beat on forward guidance forces shorts and underweight funds to chase.